Knowledge (XXG)

Hal V. Barron

Source 📝

127:
in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs. In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed
134:
On November 8, 2017, Barron became the new CSO and research chief at GlaxoSmithKline amid a shake-up from its new CEO Emma Walmsley. Barron was quoted: "GSK is a company with a rich history of innovation, with many talented scientists who care deeply about translating great science into therapies
138:
In April 2019, it was publicly reported that Barron spent excessively on travel expenses during the previous year. The total expenses exceeded $ 807,000 (£620,000). Shareholders, investors, and rank-and-file employees have all expressed concern tilting towards outrage that he has been allow to
248: 135:
that make a meaningful difference for patients. I believe there is a significant opportunity to accelerate this effort and am looking forward to joining Emma and the team on this mission.”
604: 609: 131:
On September 18, 2013, Barron was named President of Research and Development of Calico, a new company focusing on the biology of aging. The company was created and funded by Google.
599: 594: 249:"What kind of biotech startup wins a $ 3B syndicate, woos a gallery of marquee scientists and recruits GSK's Hal Barron as CEO in a stunner? Let Rick Klausner explain" 142:
In January 2022, it was announced that Barron will join Altos starting on 1 August 2022 at newly created biotech company Altos Labs, based in San Francisco.
304: 589: 202: 146: 68: 41: 475: 355: 629: 448: 619: 198: 32: 380: 614: 584: 170: 634: 624: 424:"Google announces Calico, a new company focused on health and well-being – News announcements – News from Google – Google" 95:(born 1962) is an American clinician-scientist and drug developer who served as president of research and development at 574: 564: 111:. He has served as executive vice president, head of global product development, and chief medical officer of 579: 194: 569: 100: 559: 423: 528: 359: 331: 275: 178: 174: 483: 182: 80: 112: 108: 107:
in August of that year. Prior to this he served as president of research and development at
72: 507: 449:"Roche, Calico vet Hal Barron takes GSK R&D hot seat, as Vallance out - FierceBiotech" 96: 37: 253: 553: 154: 309: 166: 150: 332:"I'm excited to announce Calico, a new company that will focus on health and w..." 356:"Roche - Roche and Genentech announce organizational and leadership decisions" 279: 162: 158: 104: 487: 139:
spend so freely while others are constrained and employee layoffs continue.
124: 76: 58: 305:"GSK's top scientist jumps ship in new blow for pharmaceutical firm" 197:
and holds a Bachelor of Science degree in engineering physics from
476:"GSK's jet-set scientist racks up travel bill worth nearly $ 800k" 99:
from March 2018 until 2022, when he resigned in order to join the
222: 201:. He completed his training in medicine and cardiology at the 405: 177:
at Alexza Pharmaceuticals, and is a current member of the
161:. He has been issued several patents for his work in 381:"Genentech: Press Releases - Tuesday, May 14, 2002" 64: 54: 28: 21: 605:University of California, San Francisco faculty 157:, and Associate Clinical Professor of Medicine/ 16:American clinician-scientist and drug developer 610:University of California, San Francisco alumni 600:Washington University in St. Louis physicists 298: 296: 8: 169:, and has published more than 80 papers in 145:Barron's current academic positions at the 18: 595:Washington University in St. Louis alumni 193:Barron received his medical degree from 214: 203:University of California, San Francisco 149:include Associate Adjunct Professor of 147:University of California, San Francisco 69:University of California, San Francisco 42:University of California, San Francisco 7: 474:Mkandawire, Vinjeru (2019-04-14). 303:Kollewe, Julia (19 January 2022). 276:"Altos Labs: Executive Leadership" 247:Carroll, John (January 19, 2022). 199:Washington University in St. Louis 33:Washington University in St. Louis 14: 171:peer-reviewed scientific journals 529:"Hal Barron – Juno Therapeutics" 590:Yale School of Medicine alumni 1: 630:American corporate directors 651: 128:executive vice president. 620:American biostatisticians 173:. He was a member of the 86: 47: 615:American epidemiologists 585:Hoffmann-La Roche people 428:Googlepress.blogspot.com 195:Yale School of Medicine 635:American transhumanists 625:American cardiologists 101:cellular reprogramming 533:Junotherapeutics.com 179:board of directors 175:board of directors 455:. 8 November 2017 453:Fiercebiotech.com 183:Juno Therapeutics 90: 89: 81:Hoffmann-La Roche 49:Scientific career 642: 575:Genentech people 565:Biotechnologists 544: 543: 541: 539: 525: 519: 518: 516: 514: 504: 498: 497: 495: 494: 471: 465: 464: 462: 460: 445: 439: 438: 436: 434: 420: 414: 413: 402: 396: 395: 393: 391: 377: 371: 370: 368: 367: 358:. Archived from 352: 346: 345: 343: 341: 328: 322: 321: 319: 317: 300: 291: 290: 288: 286: 272: 266: 265: 263: 261: 244: 238: 237: 235: 233: 219: 113:Hoffman-La Roche 73:Calico (company) 19: 650: 649: 645: 644: 643: 641: 640: 639: 550: 549: 548: 547: 537: 535: 527: 526: 522: 512: 510: 508:"Pubmed search" 506: 505: 501: 492: 490: 473: 472: 468: 458: 456: 447: 446: 442: 432: 430: 422: 421: 417: 404: 403: 399: 389: 387: 379: 378: 374: 365: 363: 354: 353: 349: 339: 337: 335:Plus.google.com 330: 329: 325: 315: 313: 302: 301: 294: 284: 282: 274: 273: 269: 259: 257: 246: 245: 241: 231: 229: 221: 220: 216: 211: 191: 121: 97:GlaxoSmithKline 38:Yale University 36: 29:Alma mater 24: 17: 12: 11: 5: 648: 646: 638: 637: 632: 627: 622: 617: 612: 607: 602: 597: 592: 587: 582: 580:GSK plc people 577: 572: 567: 562: 552: 551: 546: 545: 520: 499: 466: 440: 415: 410:calicolabs.com 397: 372: 347: 323: 292: 267: 254:Endpoints News 239: 213: 212: 210: 207: 190: 187: 123:Barron joined 120: 117: 88: 87: 84: 83: 66: 62: 61: 56: 52: 51: 45: 44: 30: 26: 25: 22: 15: 13: 10: 9: 6: 4: 3: 2: 647: 636: 633: 631: 628: 626: 623: 621: 618: 616: 613: 611: 608: 606: 603: 601: 598: 596: 593: 591: 588: 586: 583: 581: 578: 576: 573: 571: 570:Living people 568: 566: 563: 561: 558: 557: 555: 534: 530: 524: 521: 509: 503: 500: 489: 485: 481: 480:The Telegraph 477: 470: 467: 454: 450: 444: 441: 429: 425: 419: 416: 411: 407: 401: 398: 386: 382: 376: 373: 362:on 2009-04-19 361: 357: 351: 348: 336: 333: 327: 324: 312: 311: 306: 299: 297: 293: 281: 277: 271: 268: 256: 255: 250: 243: 240: 228: 224: 218: 215: 208: 206: 204: 200: 196: 188: 186: 184: 180: 176: 172: 168: 164: 160: 156: 155:Biostatistics 152: 148: 143: 140: 136: 132: 129: 126: 118: 116: 114: 110: 106: 102: 98: 94: 93:Hal V. Barron 85: 82: 78: 74: 70: 67: 63: 60: 57: 53: 50: 46: 43: 39: 34: 31: 27: 23:Hal V. Barron 20: 536:. Retrieved 532: 523: 511:. Retrieved 502: 491:. Retrieved 479: 469: 457:. Retrieved 452: 443: 431:. Retrieved 427: 418: 409: 400: 388:. Retrieved 384: 375: 364:. Retrieved 360:the original 350: 338:. Retrieved 334: 326: 314:. Retrieved 310:The Guardian 308: 283:. Retrieved 270: 258:. Retrieved 252: 242: 230:. Retrieved 226: 217: 192: 167:angiogenesis 151:Epidemiology 144: 141: 137: 133: 130: 122: 92: 91: 65:Institutions 48: 560:1962 births 538:13 February 459:13 February 433:13 February 390:13 February 340:13 February 232:13 February 554:Categories 493:2022-10-19 366:2014-06-04 280:Altos Labs 209:References 163:thrombosis 159:Cardiology 105:Altos Labs 488:0307-1235 189:Education 125:Genentech 77:Genentech 59:Physician 513:15 April 385:Gene.com 316:June 19, 227:Cnbc.com 103:venture 71:(UCSF), 285:19 June 260:19 June 223:"Wires" 486:  406:"Home" 119:Career 109:Calico 55:Fields 540:2019 515:2019 484:ISSN 461:2019 435:2019 392:2019 342:2019 318:2022 287:2022 262:2022 234:2019 165:and 153:and 181:at 556:: 531:. 482:. 478:. 451:. 426:. 408:. 383:. 307:. 295:^ 278:. 251:. 225:. 205:. 185:. 115:. 79:, 75:, 40:, 35:, 542:. 517:. 496:. 463:. 437:. 412:. 394:. 369:. 344:. 320:. 289:. 264:. 236:.

Index

Washington University in St. Louis
Yale University
University of California, San Francisco
Physician
University of California, San Francisco
Calico (company)
Genentech
Hoffmann-La Roche
GlaxoSmithKline
cellular reprogramming
Altos Labs
Calico
Hoffman-La Roche
Genentech
University of California, San Francisco
Epidemiology
Biostatistics
Cardiology
thrombosis
angiogenesis
peer-reviewed scientific journals
board of directors
board of directors
Juno Therapeutics
Yale School of Medicine
Washington University in St. Louis
University of California, San Francisco
"Wires"
"What kind of biotech startup wins a $ 3B syndicate, woos a gallery of marquee scientists and recruits GSK's Hal Barron as CEO in a stunner? Let Rick Klausner explain"
Endpoints News

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.